Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir – Yahoo Finance

The combination of ARDS-003 and Favipiravir presents viable treatments against viral infections.
Results from the PIONEER clinical trial shows Favipiravir may improve severe COVID-19 recovery and ventilator-free survival in younger patients.
Tetra and Cellvera to develop an orally administered treatment, ARDS-003, in combination with Favipiravir.
MONTREAL, Dec. 6, 2022 /CNW/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), Sepsis, and COVID-19 through PREPAiRE, an AI (Artificial Intelligence) powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclinical testing. Leveraging the power of AI enables more answers and greater insights, faster.
Results from the study demonstrate that Tetra’s investigational therapeutic, ARDS-003, which contains the active pharmaceutical ingredient Onternabez, acts against various ARDS and Sepsis targets, such as IL-6 and IL-8. Onternabez plays an important role in mitigating the inflammatory response in various targets of inflammatory conditions. Favipiravir acts against different SARS-CoV-2 targets, such as spike glycoprotein and nucleoprotein.  The interaction between Favipiravir and Onternabez against SARS-COV-2 yields a positive Molecule Synergy probability which is considered significant and justifies the combination of the two drugs to create a new therapeutic that is expected to be beneficial to increase treatment efficacy and reduce the duration of disease. Favipiravir can control the source of infection. Onternabez would contribute to the antiviral efficacy and can control the result of infection (i.e., the inflammatory response).
Dr. Guy Chamberland, CEO and Chief Regulatory Officer at Tetra commented “We are very pleased by these artificial intelligence results as well as the recent positive results from the PIONEER trial. This underscores our commitment with Cellvera to developing an innovative combination drug candidate to combat viral diseases. We are more excited than ever about our collaboration with Cellvera and the possibility of delivering the next scientific breakthroughs.”
About the PIONEER clinical trial – Cellvera’s Press Release
On October 11, 2022, Cellvera, shared an update that the UK’s Chelsea and Westminster NHS Foundation Trust sponsored PIONEER trial involving Avigan® (Favipiravir) vs. standard care confirms a reduction in deaths by 22% compared to the placebo group. Cellvera, directly or through their affiliates, holds exclusive worldwide rights to brand originator Favipiravir under the brand names Avigan® 200MG and Qifenda® 400mg/800MG and the injectable formulation. This broad-spectrum therapeutic has shown antiviral effects against SARS-CoV-2 (the virus responsible for causing COVID-19) and more than 20 other RNA viruses.
Favipiravir may improve severe COVID-19 recovery, ventilator-free survival in younger patients was the headline-grabbing statement after a presentation made by Dr/ Christopher M. Orton, MD, Consultant Respiratory Physician at Royal Brompton Hospital, London, during a presentation at the European Respiratory Society International Congress.
PIONEER: A Randomised Controlled Trial of Early Intervention in Patients Hospitalized with COVID-19: Favipiravir verses Hydroxychloroquine & azithromycin & zinc vErsEs Standard CaRe. The international PIONEER study, sponsored by Chelsea and Westminister Hospital NHS Foundation Trust, recruited 499 patients (median age, 58.9 years; 61% men) from the U.K., Brazil, and Mexico who were admitted to hospitals with proven or suspected COVID-19 from May 2020 to May 2021. Led by an expert clinical team and supported by NEAT ID, the study was financially supported by a group of leading organizations and individuals who committed funds to the trial, including Imperial College, Chelsea and Westminster Hospital NHS Foundation Trust, XTX Markets, medical research charity LifeArc, KU Leuven, and Ageas, and a broad community of individual donors.
Researchers reported that treatment with oral Favipiravir benefited recovery and mechanical ventilation-free survival among patients younger than 60 years hospitalized with COVID-19. The primary outcome was time to a 2-point improvement in the WHO ordinal scale or discharge, whichever occurred first. Secondary outcomes focused on mortality and health care resource utilization. When findings were analyzed for patients aged younger than 60 years, researchers observed a more significant numerical difference in deaths, with an approximate 50% reduction and a significant difference in mechanical ventilation-free survival (p=.02)
The PIONEER trial compared two potential antiviral treatments for early intervention in patients with COVID-19. The treatments initially selected were Avigan® (Favipiravir) and an Hydroxychloroquine/ azithromycin & zinc combination. The treatments were chosen due to their potential to be used for early intervention by inhibiting the virus’s ability to replicate and prevent the progression of the disease to the later, more severe phase. However, acting on guidance from the MHRA, the combination treatment arm of Hydroxychloroquine/azithromycin & zinc was dropped while safety issues around HCQ were being investigated. The PIONEER study continued with only one arm, that of Avigan® (Favipiravir) vs. standard care.
Research organizations involved:
Chelsea and Westminster Hospital NHS Foundation Trust
Royal Brompton Hospital
Imperial College
FUJIFILM Toyama Chemicals provided Avigan® with relevant safety information to obtain the official approvals necessary to start the trial. Favipiravir, which has a long and verified history of safety and efficacy, was initially developed by FujiFilm Toyama Chemical Co and approved in Japan (2014) to treat pandemic influenza. Favipiravir is a selective inhibitor of viral RNA-dependent RNA polymerase (RdRP) with potent antiviral activity against single-stranded RNA viruses, including coronaviruses. It targets the protein needed for the coronavirus to replicate, making it impossible for the virus to copy itself. The broad-spectrum antiviral drug is effective against 12 families of viruses, including Coronaviruses (COVID, MERS, SARS), Filoviruses (EBOLA, MARBURG), Flaviviruses (ZIKA, WEST NILE, DENGUE), RABIES, NOROVIRUS, and many others.
Mary O’ Brien Chief Executive Officer commented on data made available by Dr. Orton to colleagues at the European Respiratory Society International Congress from the PIONEER trial; “The recent presentation re-confirms the potential Favirpiravir has to save people’s lives and reduce the severity of the COVID-19 infection. We already know the profound impact Avigan® 200MG and Qifenda® 400MG has made in controlling the pandemic. It was one of the first oral antivirals to be approved as a treatment for COVID-19 and is already used by governments as the first line of defense in treating the virus. With these compelling results, and more to come, we are optimistic that Avigan® and higher strength formulations of Favirpiravir will grow as an essential drug in the global effort to fight this and future pandemics, reinforcing Cellvera’s ambition to bring forward breakthroughs in infectious diseases when they are needed most.”
About FAVIPIRAVIR
Favipiravir, discovered and developed by FUJIFILM, was first approved under the brand name Avigan® by regulators in Japan in 2014 as a potent broad-spectrum antiviral treatment for influenza. This antiviral drug is effective against 12 families of viruses, including coronaviruses (COVID, MERS, SARS), Filoviruses (EBOLA, MARBURG), Flaviviruses (ZIKA, WEST NILE, DENGUE), RABIES, NOROVIRUS, and many others. Favipiravir works by inhibiting a viral enzyme called RNA polymerase, preventing viral replication within human cells. Favipiravir has potent antiviral activity against single-stranded RNA viruses, including coronaviruses. This is the protein responsible for “building” the viral proteins. Favipiravir can target the protein necessary for the coronavirus to replicate, making it impossible for the virus to copy itself.
About Cellvera
Cellvera is a biopharmaceutical company focused on discovering, developing, and commercializing oral therapies and monitoring tools to address the unmet medical needs of patients with life-threatening viral diseases.
Leveraging the Company’s deep understanding of antiviral drug development, nucleotide chemistry, biology, biochemistry and virology, Cellvera has built a nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases.
Currently, Cellvera is focused on the clinical and commercial development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). Driven to Discover. Cellvera’s team includes PhDs in computational biology, biochemistry, and chemistry, as well as senior software engineers. www.cellvera.com
About Global Response Aid (GRA)
Agility (KSE/DFM: AGLTY), one of the world’s leading logistics companies and CELLVERA, an innovative pharma research, development and commercialization company based in Dubai, established Global Response Aid (GRA) to address the market challenges created by the COVID-19 pandemic and other threats to public health. GRA delivers innovative, effective healthcare solutions through a range of pharmaceutical products and technology platforms. It works closely with governments, regulatory authorities, hospitals, clinics, healthcare providers, life sciences companies, NGOs and public institutions to develop strategies that allow them to tackle public health challenges. For more information: www.globalresponseaid.com
About FUJIFILM
FUJIFILM Corporation, Tokyo, Japan is one of the major operating companies of FUJIFILM Holdings Corporation. The company brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information holdings.fujifilm.com
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of this product  or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tetra-bio-pharma-announces-results-of-artificial-intelligence-study-of-ards-003-combined-with-favipiravir-301695202.html
SOURCE Tetra Bio-Pharma Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2022/06/c0699.html
Related Quotes
Deputies responded to the Tymber Skan apartment complex off Texas Avenue just before 2 a.m.
Gossamer Bio Inc (NASDAQ: GOSS) announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH). A mean difference in pulmonary vascular resistance (PVR) between the placebo and seralutinib arms of -96.1 dynes, equating to a placebo-corrected improvement of 14.3%, was observed in the study. An observed mean difference in six-minute walk distance (6MWD) between placebo and seralutinib of 6.5 meters numerically favored the seralutinib ar
Only last week, the company was warned about its stock price; this week it's looking at putting a premium on the price of its second FDA-approved drug.
The company focuses on therapies to treat chronic debilitating conditions and after the market closed on Monday, it released phase 2 trial results for its lead therapy, NE3107, to treat Alzheimer's disease and Parkinson's disease. The therapy was more effective (6 points) higher when used on Parkinson's patients who were under 70. BioVie also tested NE3107 as a monotherapy in mild Alzheimer's patients and said patients showed 2.1 points of improvement in enhanced cognition on the modified Alzheimer's Disease Assessment Scale (ADAS).
Consider, for instance, Editas Medicine (NASDAQ: EDIT) and BioXcel Therapeutics (NASDAQ: BTAI). Let's consider why Editas Medicine and BioXcel Therapeutics are worth keeping an eye on right now, and whether the potential rewards of investing in these companies outweigh the risks. The company is down by 61% this year, a terrible performance it partly owes to market-wide troubles.
The FDA has a bevy of safety concerns surrounding Verve's gene-editing approach to high cholesterol, leading VERV stock to crash Monday.
Emergent BioSolutions Inc. (NYSE: EBS) has cleared an important hurdle in a bid to make its opioid overdose antidote available to the public without a doctor’s order. The Gaithersburg company said Tuesday that the Food and Drug Administration has accepted its supplemental new drug application for Narcan Nasal Spray, currently available with a prescription, as an emergency over-the-counter treatment for opioid overdose. The FDA expects to issue its decision of approval or denial March 29, 2023.
Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity.
Her friend and co-star John Travolta called her one of the "most special relationships I’ve ever had."
Investing in small-cap stocks can be very risky. Let's consider two small-cap stocks that carry above-average risk but that could soar as early as next year if things work out: Bluebird Bio (NASDAQ: BLUE) and Krystal Biotech (NASDAQ: KRYS). Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses.
In its response to a lawsuit brought by Covid-19 vaccine competitor Moderna Inc., Pfizer Inc. does not mince words: Pfizer did not copy Moderna's patented technology, it says, and Moderna is rewriting history by claiming otherwise.
The data presented for Eisai and Biogen’s drug wasn’t convincing enough to settle a debate among experts, but investors are betting on commercial success anyway.
Editas Medicine Inc (NASDAQ: EDIT) announced initial clinical data from the first two sickle cell disease (SCD) patients treated with EDIT-301 in the Phase 1/2 RUBY trial. EDIT-301 is under development for the treatment of severe sickle cell disease. The clinical data includes safety data from the first two patients and efficacy data from the first patient treated. Both treated patients demonstrated successful neutrophil and platelet engraftment. Additionally, neither patient has experienced any
Shares of Gossamer Bio Inc. plunged 64.5% in premarket trading on Tuesday after Wall Street analysts questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial. Though Gossamer said the drug, seralutinib, met the primary endpoint in a Phase 2 clinical trial, SVB Securities analyst Joseph Schwartz told investors that the therapy didn't outperform Merck & Co. Inc.'s sotatercept. "We expect the street to be disappointed in these topline results given both
A for-profit California company saw windfall dividend — and patients scrambled for care, a CBS News investigation found.
Soligenix Positioned for Growth: Late-stage Pipeline and Key Q4 Milestones
By Exec Edge Editorial Staff Until recently, DNA tests have been costly and inaccessible for many individuals, researchers, and clinicians. But, over the past seven years, Andrea Riposati and Mattia Capulli’s global genomics and precision medicine company, Dante Labs, has made these tests more accessible to people all over the world. Dante Labs uses the […]
A Texas woman is out on bond after authorities say she repeatedly stabbed her boyfriend on Thanksgiving after accusing him of “not helping her with the bills,” according to court records. Cassandra Gutierrez, 30, was released on bond Thursday after being charged with aggravated assault with a deadly weapon for the alleged stabbing, which left her boyfriend injured but alive, Law & Crime reports. Gutierrez and her 42-year-old boyfriend had been dating for about a year when investigators said they
(Bloomberg) — China is set to announce a further relaxation of Covid control measures as soon as today — including allowing some infected people to home quarantine as a nationwide policy, and reining in unnecessary testing — according to people familiar with the matter, as the government continues to quickly ease its zero-tolerance strategy amid growing public discontent. Most Read from Bloomberg‘Huge, Missing and Growing:’ $65 Trillion in Dollar Debt Sparks ConcernWall Street Goes Risk Off as
SimpleImages / GettyThe fight against COVID seems to have fallen into a ping-ponging rhythm at this point, where every step forward seems undercut by one backward. Vaccines are available, and hospitalization rates have fallen dramatically from previous peaks. But just a sliver of eligible Americans have received the most recent bivalent shot, and the specter of a new, somehow worse variant looms large in our collective psyche. Elsewhere, such as in China, we seem to be losing ground to the virus

source